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Abstract: The use of non-steroidal anti-inﬂ  ammatory drugs has become ubiquitous worldwide 
and remains a common source of gastrointestinal morbidity. Antisecretory medications, particu-
larly proton pump inhibitors, are effective in the treatment and prevention of NSAID-related 
gastrointestinal complications, including peptic ulcer disease and non-ulcer dyspepsia. A careful 
assessment of patients’ risk factors for developing NSAID-related gastrointestinal complications 
should be undertaken prior to initiation of any NSAIDs. Patients who are considered at risk 
for developing gastrointestinal complications should receive concurrent antisecretory medical 
therapy to minimize the risk for GI complications.
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Introduction
Over one hundred million prescriptions for non-steroidal anti-inﬂ  ammatory drugs 
(NSAIDs) were written in the US in 2000,1 mostly for chronic pain syndromes and 
rheumatologic conditions. This likely represents only a fraction of NSAID use in the 
US due to the difﬁ  culty with tracking readily available over the counter (OTC) forms of 
these drugs, including aspirin and non-aspirin NSAIDs. Due to the aging population in 
the Western world the use of aspirin for the chemoprevention of cardiovascular, cere-
brovascular, peripheral vascular disease and metabolic syndrome is likely to continue 
to increase. The recent widely publicized concerns regarding increased cardiovascular 
risks associated with cyclo-oxygenase-2 (COX-2) selective inhibitors has also con-
tributed to increased use of non-selective NSAIDs.2 The use of non-selective NSAIDs 
may further increase with recent interest in use of these drugs for the chemoprevention 
of colorectal cancer,3 breast cancer,4 and Alzheimer’s disease.5
In spite of being among the most widely prescribed pharmaceuticals in the world, 
NSAIDs have long been recognized as a major cause of gastrointestinal morbidity. 
NSAID-associated gastrointestinal complications range from dyspepsia without endo-
scopic ﬁ  ndings to severe complications such as ulcer-related perforation, obstruction, 
or hemorrhage. The use of chronic NSAIDs increases the risk of peptic ulcer disease 
complications by 3- to 5-fold. Overall, 15%–35% of all peptic ulcer complications 
are reportedly related to chronic NSAID use.6 Moreover, major adverse gastrointes-
tinal events attributed to NSAIDs are responsible for over 100,000 hospitalizations, 
US$2 billion in healthcare costs, and 17,000 deaths in the US each year.7 Despite 
improvements in the available medications to aid in healing and treatment of NSAID-
associated complications, the number of hospitalizations and deaths has remained 
unchanged in the US in the last decade. While clinically signiﬁ  cant complications such 
as perforation, obstruction, or hemorrhage are relatively uncommon (1%–2% of all 
NSAID users, overall incidence of 2%–4% per year),8 gastrointestinal symptoms includ-
ing nausea, heartburn, dyspepsia, and abdominal pain are extremely common and may Therapeutics and Clinical Risk Management 2009:5 66
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occur in up to 40% patients taking chronic NSAIDs.9,10 
Despite being clinically effective in treating the underlying 
disease, gastrointestinal symptoms may negatively impact 
quality of life enough to warrant either dose reduction or 
discontinuation of the drug.11 Certain groups of persons taking 
NSAIDs are at increased risk for developing NSAID-related 
complications, including patients with prior history of peptic 
ulcer disease, the elderly, patients taking high dose NSAIDs, 
and patients taking concurrent anticoagulation or corticoste-
roids.12,13 Therapeutic strategies to reduce NSAID-associated 
gastrointestinal complications have focused on the treatment 
of acute events such as peptic ulcer disease and the preven-
tion of future events in patients who continue taking chronic 
NSAIDs. Historically, the most widely employed prevention 
strategies involved either cyclo-oxygenase 2 (COX-2) selec-
tive inhibitors or co-administration of a nonselective NSAID 
with a proton pump inhibitor. This paper will review medical 
therapy for primary treatment and the indications for primary 
and secondary prophylaxis for NSAID-associated gastro-
intestinal complications including peptic ulcer disease and 
non-ulcer dyspepsia.
Pathogenesis of NSAID-associated 
peptic ulcer disease
Non-steroidal anti-inﬂ  ammatory medicines and Helicobacter 
pylori are known to independently and signiﬁ  cantly increase 
the risk for gastroduodenal ulcer and ulcer bleeding. This 
has important diagnostic and treatment implications as both 
ulcerogenic factors are highly prevalent. Moreover, the 
relationship between H. pylori infection and NSAID use has 
important diagnostic and treatment implications, particularly 
in patients who take NSAIDs and have concurrent H. pylori 
infection. While it is generally thought that H. pylori infection 
and NSAIDs induce mucosal damage by different mechanisms, 
there is ongoing debate whether their coincidence is indepen-
dent, additive, synergistic, or antagonistic.14 Whether or not 
eradication of H. pylori modiﬁ  es the ulcer risk in patients who 
require chronic NSAIDs remains a topic of debate.
Mucosal injury caused by NSAIDs likely occurs by several 
different mechanisms and can be broadly divided into topical 
and systemic effects. Most NSAIDs, including aspirin, are 
carboxylic acid derivatives and consequently are not ionized 
in the acidic pH found in the stomach. The nonionized drug is 
readily absorbed across the gastric mucosa into the pH-neutral 
mucosa where it is ionized and temporarily trapped within 
the epithelial cells. The high intracellular concentration of 
drug may induce cellular injury and ultimately cause damage 
to the gastrointestinal mucosa.
The systemic effects exhibited by the post-absorptive 
inhibition of gastrointestinal cyclooxygenase (COX) 
activity likely plays a more central role in the pathogenesis 
of NSAID-induced ulcers. Indeed, peptic ulcer disease has 
been demonstrated in humans following the intravenous and 
intramuscular administration of NSAIDs, which suggests a 
systemic mechanism of action.15,16 Cyclooxygenase, which 
is present in at least two isoforms in humans, is the principal 
enzyme involved in the biochemical conversion of membrane 
phospholipid, arachidonic acid, into prostaglandins. 
Various prostaglandins may either prevent or potentiate the 
inﬂ  ammatory response. Like most tissue, healthy gastric 
and duodenal mucosae constitutively express COX-1, which 
produces prostaglandins that act locally in the stomach and 
duodenum to help protect against mucosal injury. In contrast, 
the expression of COX-2 occurs largely in response to 
inﬂ  ammatory mediators and generates various prostaglandin 
effectors that are responsible for attenuating the inﬂ  ammatory 
response.
NSAIDs exert their effects by interfering with 
prostaglandin production through the direct inhibition of 
cyclooxygenase activity. From a gastrointestinal standpoint, 
the ideal NSAID would inhibit the inducible COX-2 isoform, 
thereby reducing inﬂ  ammation, without acting on COX-1 and 
its constitutively expressed cytoprotective effectors. Most 
NSAIDs, including aspirin and ibuprofen inhibit COX-1 and 
COX-2 equally. However, some NSAIDs, such as celecoxib, 
selectively inhibit COX-2 and exhibit less suppression on 
the locally protective gastric prostaglandins. The inhibition 
of COX-1 and the loss of the protective gastrointestinal 
prostaglandins may cause a local ischemic injury by reduction 
in mucosal blood ﬂ  ow at the submucosal and mesenteric 
levels.17,18 While associated with less gastrointestinal toxicity, 
selective COX-2 inhibitors are still associated with some risk 
for gastrointestinal toxicity particularly at higher doses and in 
high risk patients.19,20 Recently publicized concerns regarding 
the increased cardiovascular and thromboembolic risk in 
patients taking selective COX-2 inhibitors and high doses of 
some nonselective NSAIDs has led to a global re-evaluation 
of the use of these drugs in clinical practice.21 Novel drugs 
with improved safety proﬁ  le throughout their therapeutic 
range which selectively inhibit COX-2 are desirable and will 
likely reduce adverse gastrointestinal events.
Medical therapy for NSAID-
associated peptic ulcer disease
The treatment of peptic ulcer disease in patients who test 
negative for H. pylori relies on prompt discontinuance of the Therapeutics and Clinical Risk Management 2009:5 67
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potential causative agent, such as NSAIDs, and the initiation 
of medical therapy to promote ulcer healing. Options for 
medical treatment include cytoprotective agents including 
sucralafate and the prostaglandin analogue misoprostol, 
the latter aims to restore the prostaglandins which become 
depleted by COX-1 inhibition. Acid-suppressive agents 
including histamine-2 antagonists (H2RAs) and proton 
pump inhibitors (PPIs) have also been employed as medical 
therapy.
Primary treatment of NSAID-associated 
peptic ulcer disease
Whenever possible, the primary treatment for NSAID-
associated peptic ulcer disease should include discontinuing 
potential causative agents. In some instances this may 
not be possible due to concerns that the underlying 
chronic disease being treated may worsen if therapy is 
stopped. This commonly occurs in patients with vascular 
diseases, especially coronary artery disease, which may 
pose high risk if antiplatelet therapy such as aspirin is 
discontinued.
Numerous studies have evaluated endoscopic ulcer 
healing rates in the context of continued NSAID use. It is 
important to recognize that studies using endoscopic healing 
rates as a primary end point may not be clinically signiﬁ  cant 
as most ulcers endoscopic ulcers do not cause clinically 
signiﬁ  cant complications such as perforation, obstruction, 
or hemorrhage. The use of H2RAs has been widely studied 
in the treatment of acid-related disorders. Endoscopic 
healing rates of gastric and duodenal ulcerations have been 
reported between 50%–84% after 8 weeks of treatment, 
with higher healing rates generally observed with treatment 
of duodenal ulcers.22 Lancaster-Smith, et al performed a 
multi-center endoscopic surveillance study on 190 patients 
with conﬁ  rmed gastric or duodenal ulcerations attributed 
to NSAIDs.23 All patients received ranitidine 150 mg twice 
daily and were randomized to either continue or discontinue 
NSAID treatment. The 8-week endoscopic healing rates were 
95% and 100% for gastric and duodenal ulcers, respectively, 
in patients who received H2RA and discontinued NSAIDs. 
The authors noted that healing rates were much lower 
(63% and 84% for gastric ulcer and duodenal healing, 
respectively) in patients treated with H2RA who remained 
on NSAIDs throughout the treatment period.23 Manniche 
et al performed an open-label study comparing ranitidine 
150 mg twice daily with sucralafate 1 g 4 times daily in 
patients with NSAID-associated peptic ulcer disease.24 Half 
of the patients in each treatment group were allowed to 
continue NSAID therapy while the other half was given an 
alternative non-NSAID analgesic medication. The overall 
healing rates were comparable between the two groups (81% 
for ranitidine, and 84% for sucralafate) at 9 weeks. Healing 
rates were improved in patients who discontinued NSAIDs 
during primary treatment, 92% versus 85%, respectively.24 
There have been no randomized trials to date comparing 
misoprostol to H2RAs in the primary treatment of NSAID-
associated peptic ulcer disease.
The extent of gastroduodenal mucosal damage caused 
by NSAIDs is highly dependent on the intraluminal gastric 
pH. Low intragastric pH enhances the diffusion of NSAIDs 
into the gastric mucosa and may facilitate mucosal injury.25 
Moreover, H2RAs have been associated with variations in 
24-hour acid suppression.26 The profound and sustained acid 
suppressive effects exhibited by proton pump inhibitors have 
revolutionized the treatment of acid-related gastrointestinal 
diseases. Amongst patients continuing chronic NSAIDs 
and taking proton pump inhibitors, once-daily esome-
prazole (74.2%) has been shown to have a greater mean 
percentage time with gastric pH   4 during 24-hour pH 
monitoring compared to once-daily lansoprazole (66.5%) 
and pantoprazole (60.8%).27
Multiple clinical trials have evaluated ulcer healing 
rates using proton pump inhibitors in chronic NSAID users. 
The Acid Suppression Trial: Ranitidine versus Omeprazole 
for NSAID-Associated Ulcer Treatment (ASTRONAUT) 
trial (Yeomans, et al) studied 541 patients who required 
continuous NSAIDs and had demonstrable peptic ulcer 
disease.28 Patients were randomized to receive either 20 mg 
or 40 mg omeprazole daily, or 150 mg ranitidine twice daily 
and were followed for endoscopic healing. At eight weeks, 
treatment was successful in 80% of the patients in the 
20 mg omeprazole group, 79% of the patients in the 40 mg 
omeprazole group, and 63% of the patients in the ranitidine 
group. Following endoscopic resolution, signiﬁ  cantly more 
patients remained in remission at 6-month follow-up in 
the group receiving omeprazole (72%) than the ranitidine 
group (59%). The authors concluded that omeprazole is 
superior to ranitidine in healing and preventing recurrence 
of NSAID-associated ulcers in patients who use chronic 
NSAIDs.28
In the multi-national, double-blind Omeprazole versus 
Misoprostol for NSAID-Induced Ulcer Management 
(OMNIUM) study, Hawkey, et al randomly assigned 
935 patients with established NSAID-associated ulcers to 
receive either 20 mg omeprazole daily, 40 mg omeprazole 
daily, or 200 μg misoprostol four times daily while remaining Therapeutics and Clinical Risk Management 2009:5 68
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on NSAID therapy.29 Endoscopic healing rates were higher 
in the omeprazole groups (76% in group receiving 20 mg, 
and 75% in group receiving 40 mg) compared with the 
misoprostol group (71%). Once endoscopic healing was 
achieved, 732 patients were treated for 6 months with 
maintenance therapy, either 20 mg omeprazole, 200 μg 
misoprostol twice daily, or placebo. Signiﬁ  cantly more 
patients remained in remission with omeprazole (61%) 
than with misoprostol (48%) and with either drug than with 
placebo (27%) during the 6 month maintenance treatment 
period.29 It is worth noting that maintenance treatment 
dose of misoprostol was lower than approved doses. The 
authors concluded that both doses of omeprazole were 
similar to misoprostol in the treatment of NSAID-associated 
peptic ulcer disease. In addition, maintenance therapy with 
omeprazole was associated with a lower rate of relapse 
than misoprostol and was better tolerated than misoprostol 
due to treatment associated diarrhea and abdominal pain. 
Another large, prospective, double-blind, multi-center study 
evaluated 537 patients with endoscopic-proven gastric ulcers 
attributed to NSAIDs. This study addressed some of the 
limitations in the ASTRONAUT and OMNIUM trials by 
ensuring that all patients tested negative for Helicobacter 
pylori at the time of enrollment. Prior studies have shown 
that gastoduodenal outcome in chronic NSAID users who 
are infected with H. pylori is different than patients without 
infection.30,31 In addition, the misoprostol treatment arm used 
approved treatment doses of the drug during the entire treat-
ment period. Graham, et al randomized patients to treatment 
with either placebo, 200 μg misoprostol four times daily, or 
lansoprazole (15 mg or 30 mg) daily and were allowed to 
continue NSAIDs during the six month treatment period.32 
Patients were followed with serial endoscopic evaluations 
at 4, 8, and 12 weeks during treatment. The 12-week gastric 
ulcer-free rates were signiﬁ  cantly higher in the groups treated 
with lansoprazole (80% and 82%, in 15 mg and 30 mg 
lansoprazole, respectively) and misoprostol (93%) compared 
to placebo (51%). The authors also noted that while effective 
in prevention of gastric ulcer relapse, the misoprostol 
treatment group had a signiﬁ  cantly higher rate of treatment-
related side effects and early withdrawal compared to the 
lansoprazole group.32 Goldstein et al performed a similar 
study comparing 20 mg or 40 mg esomeprazole and ranitidine 
150 mg twice daily in 406 patients receiving NSAIDs with 
endoscopically conﬁ  rmed peptic ulcer disease.33 The 8-week 
healing rates with esomeprazole 40 mg and 20 mg were 
91.5% and 88.4%, respectively, and were signiﬁ  cantly higher 
than the 74.2% rate with ranitidine.33
Secondary prophylaxis of NSAID-induced 
peptic ulcer disease
Once resolution of NSAID-associated peptic ulcer 
disease has been demonstrated, a careful assessment of 
risks and beneﬁ  ts of continued NSAID therapy should 
be undertaken before reinitiation or continued NSAID 
therapy. A number of risk factors have been identiﬁ  ed 
that may be helpful in predicting an increased risk for 
NSAID-related complications (Table 1). Importantly, a 
history of complicated peptic ulcer disease and use of 
multiple NSAIDs are the major risk factors for recurrent 
complications with odds ratios of 13.5 and 9, respectively. 
Prevention strategies are recommended in patients with 
significant risk factors who are unable to discontinue 
NSAIDs or who have high risk medical comorbidities 
that favor continued NSAID therapy, particularly in those 
patients with cardiovascular or cerebrovascular disease who 
require continued aspirin therapy.
Two large similarly designed randomized, double-
blind, placebo-controlled trials assessed ulcer prevention 
in high-risk patients who were either  60 years of age 
and/or had documented peptic ulcer disease within ﬁ  ve 
years prior to enrollment.34 All patients were on stable 
doses of NSAIDs (including COX-2 inhibitors) for at least 
4 weeks prior to the study, tested negative for H. pylori, 
and had no endoscopic ﬁ  ndings to suggest peptic ulcer 
disease at time of enrollment. The Veriﬁ  cation of Esome-
prazole for NSAID Ulcers and Symptoms (VENUS) study 
performed in 110 centers throughout the United States and 
the international equivalent, Prevention of Latent Ulcer-
ation Treatment Options (PLUTO) study, enrolled a total 
of 844 and 585 patients, respectively, all of whom were 
randomized to receive either 20 mg or 40 mg esomeprazole 
Table 1 Risk factors for development of peptic ulcer disease related 
to nonsteroidal anti-inﬂ  ammatory drugs52,53,54,55,56,57
Risk factor Risk equivalent
Prior history of complicated PUD OR 13.5
Multiple ( 2) NSAIDs OR 9
Co-administration of NSAID + aspirin SIR 5.6
High dose NSAIDs OR 7
Co-administration NSAID + anticoagulant OR 6.4
Prior history of uncomplicated PUD OR 6.1
Age   70 OR 5.6
Co-administration of NSAID + corticosteroids OR 2.2
Abbreviations: PUD, peptic ulcer disease;   OR, odds ratio; SIR, standardized inci-
dence ratio.Therapeutics and Clinical Risk Management 2009:5 69
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or placebo daily for 6 months. Patients were assessed for 
development of upper GI symptoms and underwent physi-
cal examination and upper endoscopy at baseline and after 
1, 3, and 6 months of treatment. The estimated proportion 
of patients developing peptic ulcer disease over the 6-month 
study period in the VENUS study was 20.4% on placebo, 
5.3% on 20 mg esomeprazole, and 4.7% on 40 mg esome-
prazole daily. The estimated proportions were similar in the 
PLUTO study 12.3% on placebo, 5.2% on 20 mg esome-
prazole, and 4.4% on 40 mg esomeprazole daily. A similar 
risk reduction was observed in patients taking esomeprazole 
regardless of whether patients were taking non-selective 
NSAIDs or COX-2 inhibitors. The authors concluded that 
for high risk patients, esomeprazole was well-tolerated and 
effective in preventing peptic ulcer disease in patients taking 
chronic NSAIDs.34
Combination treatment with a proton pump inhibi-
tor and a selective COX-2 inhibitor has been suggested 
for optimal gastrointestinal protection in the highest risk 
patients, particularly those who have had complicated 
peptic ulcer disease. Chan, et al evaluated 273 patients 
with documented NSAID-associated peptic ulcer disease. 
After endoscopic healing was conﬁ  rmed and H. pylori 
(if present) was eradicated, all patients were started on 
celecoxib 200 mg twice daily and randomized to either 
esomeprazole 20 mg twice daily or placebo for 12 months. 
The primary end point of recurrent ulcer bleeding was 0% in 
the esomeprazole group and 8.9% in the placebo group. The 
authors concluded that esomeprazole plus celecoxib was 
superior to celecoxib alone for the prevention of recurrent 
ulcer bleeding in patients with history of NSAID-induced 
ulcer bleeding.35
Primary prophylaxis of NSAID-induced 
peptic ulcer disease
It is widely accepted that antisecretory medications, 
particularly proton pump inhibitors, are effective in the 
primary treatment and prevention of recurrent NSAID-
associated peptic ulcer disease. Primary prophylaxis for 
prevention of gastrointestinal complications in chronic 
NSAID users has been more controversial
Raskin et al compared misoprostol and ranitidine in 
538 chronic NSAID users with normal baseline upper 
endoscopy. Misoprostol was shown to be signiﬁ  cantly 
more effective in the prevention of NSAID-induced 
gastric ulcers compared to the H2RA ranitidine (0.56% 
versus 5.67%) in the 8-week trial period. Prevention rates 
were similar between misoprostol (1.10%) and ranitidine 
(1.08%) for duodenal ulcers, but ranitidine was better 
tolerated.36 The multinational Omeprazole versus Placebo 
as Prophylaxis against ULcers or Erosions from NSAID 
Treatment (OPPULENT) study conducted by Cullen, et al 
evaluated the primary prevention of peptic ulcer disease 
using once daily omeprazole (20 mg) versus placebo in 
169 patients taking chronic NSAIDs with no demonstrable 
peptic ulcer disease. A total of 16.5% patients treated with 
placebo developed gastric or duodenal ulcerations com-
pared to only 3.6% patients treated with omeprazole during 
the six month treatment period.37 Regula et al performed 
another primary prevention study evaluating the use of 
daily pantoprazole (20 mg or 40 mg), omeprazole (20 mg) 
in 595 chronic NSAID users with no evidence of peptic 
ulcer disease on baseline upper endoscopy. After 6 months, 
the probabilities to remain in remission in the pantoprazole 
groups were 90% and 93% (20 mg and 40 mg, respectively) 
and 89% in the omeprazole group. The authors concluded 
that both doses of pantoprazole and omeprazole provide 
equivalent, effective, and well-tolerated primary prophy-
laxis against the endoscopic development of peptic ulcer 
disease in chronic NSAID users.38
While most COX-2 inhibitors are no longer widely 
available due to safety concerns, these drugs provided an 
alternative strategy in primary and secondary prophylaxis 
of gastrointestinal complications related to chronic 
NSAIDs. Several large outcomes studies have demonstrated 
signiﬁ  cantly fewer clinically important upper gastrointestinal 
events in patients treated with selective COX-2 inhibitors 
compared to non-selective NSAIDs.9,39,40 In the Vioxx 
GI Outcomes Research (VIGOR) study, patients with 
rheumatoid arthritis were assigned to receive full treat-
ment doses of either naproxen or rofecoxib and followed 
for gastrointestinal complications such as hemorrhage, 
perforation, or obstruction. Overall, the rofecoxib group 
showed a 40% relative risk reduction in GI complications 
compared to the naproxen group. By contrast, the Celecoxib 
Long-term Arthritis Safety Study (CLASS), which compared 
treatment doses of celecoxib and diclofenac, demonstrated 
similar rates of ulcers and ulcer complications between 
the two groups. A post hoc analysis suggested that lack 
of difference was due to the relatively large number of 
patients in the celecoxib group allowed to take concomitant 
low-dose aspirin for primary and secondary prevention of 
cardiovascular and cerebrovascular disease. Whether aspirin 
abrogates the potentially protective beneﬁ  ts of selective 
COX-2 inhibitors remains controversial and patients 
receiving both aspirin and a selective COX-2 inhibitor may Therapeutics and Clinical Risk Management 2009:5 70
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require prophylactic antiulcer therapy if they are at risk for 
gastroduodenal toxicity.
Secondary prophylaxis of NSAID-induced 
peptic ulcer disease using other 
antiplatelet agents
Aspirin has a known dose-related risk of gastrointestinal 
adverse events, particularly in elderly patients.41 New 
antiplatelet drugs, such as the adenosine diphosphate receptor 
inhibitor clopidogrel, have been proposed as an alternative 
therapeutic medication in the prevention and treatment of 
vascular diseases. The 2000 American College of Cardiology-
American Heart Association Guidelines recommended the 
use of clopidogrel for hospitalized patients with coronary 
syndromes who are unable to take aspirin because of major 
gastrointestinal intolerance.42 This has prompted investigators 
to evaluate the risk of recurrent ulcer bleeding using other 
antiplatelet medications. Chan et al randomized 320 patients 
with a history of peptic ulcer disease attributed to aspirin to 
receive 75 mg clopidogrel daily with placebo twice daily or 
80 mg aspirin daily with 20 mg esomeprazole twice daily.43 
All patients tested negative for H. pylori and had endoscopi-
cally conﬁ  rmed ulcer healing prior to enrollment. During 
the 12 month treatment period, a total of 13 patients in the 
clopidogrel group developed a recurrent ulcer bleed compared 
to 1 patient in the aspirin plus esomeprazole group. The 
cumulative 12-month incidence was 8.6% for clopidogrel 
versus 0.7% for aspirin with esomeprazole. The authors 
concluded that the risk of gastrointestinal bleeding in the 
aspirin plus esomeprazole group was signiﬁ  cantly lower than 
the clopidogrel group and therefore superior in the prevention 
of recurrent ulcer bleeding.43 While the mechanism remains 
unknown, this study provides supportive evidence that clopi-
dogrel poses a signiﬁ  cant risk of peptic ulcer disease and does 
not support the proposed 2000 ACC/AHA guidelines for 
use of clopidogrel in patients with previous gastrointestinal 
intolerance.
The withdrawal of some COX-2 inhibtors (rofecoxib and 
valdecoxib) from global markets has led to new prevention 
strategies against upper GI complications. The potential 
protective effects of nitrovasodilators are of particular interest 
considering that concurrent use of aspirin and nitrates is 
common in patients with cardiovascular disease. Nitrates and 
nitric-oxide releasing drugs are believed to exert their protective 
effects by maintaining mucosal blood ﬂ  ow at the level of 
the gastroduodenal microcirculation, thereby counteracting 
one of the principal deleterious effects of COX-1 inhibition. 
Indeed, both experimental and epidemiological studies have 
consistently demonstrated a reduced risk of gastroduodenal 
damage and ulcer bleeding with concomitant use of nitrates 
or nitric-oxide releasing agents and NSAIDs.44,45,46 A recent 
case-control study by Lanas, et al analyzed the concomitant 
use of anti-secretory medications and nitrates on the risk 
of ulcer bleeding in 2777 consecutive patients with upper 
gastrointestinal hemorrhage compared to 5532 controls.47 The 
use of NSAIDs (including aspirin at any dose) was associated 
with an increased relative risk (RR) of upper gastrointestinal 
hemorrhage (RR 5.6, 95% CI 5.0–6.3). Consistent with pre-
vious data, the concomitant use of proton pump inhibitors, 
H2RAs, and nitrates was associated with an 82%, 61%, and 
49% reduction in risk of upper gastrointestinal hemorrhage, 
respectively. When patients were stratiﬁ  ed according to the use 
of other antiplatelet agents (eg, clopidogrel) or anticoagulants 
(eg, dicumarinics), the RR of upper gastrointestinal hemorrhage 
was 3.2 (95% CI 2.2–4.4 and 95% CI 2.5–4.0, respectively), 
which is comparable to risk associated with low dose aspirin. 
Interestingly, only concomitant use of proton pump inhibitors 
and not H2RAs or nitrates was associated with risk reduction 
in patients taking non-NSAID antiplatelet medications (81%) 
and none of these preventive agents were associated with a 
statistically signiﬁ  cant risk reduction among anticoagulant 
users. The authors concluded that based on these observa-
tional data, there was a clear beneﬁ  t from co-administration of 
antisecretory drugs and nitrates in prevention of upper GI peptic 
ulcer bleeding associated with NSAIDs, including aspirin. 
Moreover, these data suggest that profound acid suppression as 
exhibited by proton pump inhibitors may prevent ulcer bleeding 
in patients treated with non-NSAID antiplatelet drugs.
Treatment of NSAID-associated 
gastrointestinal symptoms
Another important aspect in the treatment of NSAID-associated 
gastrointestinal complications relates to the treatment of upper 
GI symptoms associated with chronic NSAID use. Indeed, 
as many as 40% patients treated with chronic NSAIDs may 
experience upper gastrointestinal symptoms such as dyspepsia, 
abdominal pain, and heartburn.10 It is important to realize, 
however, studies have demonstrated little correlation between 
gastrointestinal symptoms and endoscopic ﬁ  ndings in patients 
taking chronic NSAIDs. For example, in one study 46% of 
asymptomatic patients taking low dose aspirin (100–325 mg 
daily) had ulcerations found in the stomach or duodenum at 
time of endoscopy.48 In another study, the ﬁ  rst sign of a peptic 
ulcer disease was a life-threatening complication in 58% of 
patients using chronic NSAIDs.49 Nonetheless, many patients 
require NSAIDs to control their primary underlying chronic Therapeutics and Clinical Risk Management 2009:5 71
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disease and cannot tolerate dose reduction, interruption, 
or discontinuation of the drug. Multiple studies have been 
conducted to address whether antisecretory agents are effective 
in controlling gastrointestinal symptoms related to NSAIDs 
despite the absence of endoscopic ﬁ  ndings. Hawkey et al per-
formed a large multicenter trial to evaluate the clinical response 
in upper gastrointestinal symptoms attributed to NSAIDs 
(including COX-2 inhibitors) treated with esomeprazole.50 
A total of 608 and 556 chronic NSAID users, respectively, 
were randomized to treatment in the two identical Nexium 
Anti-Inﬂ  ammatory Symptom Amelioration (NASA1) and 
Symptoms Prevention by Acid Control with Esomeprazole 
(SPACE1) protocols. All patients were endoscopically free 
of gastroduodenal ulcerations, erosive esophagitis, and tested 
negative for H. pylori at enrollment. Patients were continued 
on previously stable doses of NSAIDs and were randomized to 
treatment with either once daily esomeprazole (20 mg or 40 mg) 
or placebo. A standardized gastrointestinal symptom rating 
scale (GSRS) was used to measure patient-reported upper GI 
symptoms including reﬂ  ux, abdominal pain, and indigestion on 
a 7-point severity scale at baseline and after 4 weeks of medical 
therapy. The primary endpoint was the patients’ mean change 
in the upper GI symptom score between baseline and the end 
of the study. Patients in both the NASA1 and SPACE1 trials 
treated with both doses of esomeprazole had highly signiﬁ  cantly 
improvement in symptoms based on mean change in GSRS 
(2.30 and 2.17 on 20 mg esomeprazole for NASA1 and 
SPACE1, respectively; 2.03 and 2.12 on 40 mg esomeprazole 
for NASA1 and SPACE1, respectively) compared to placebo 
(1.64 and 1.56 for NASA1 and SPACE1, respectively). The 
improvement in upper GI symptoms occurred in patients 
regardless of whether they were taking non-selective NSAIDs 
or COX-2 inhibitors. The authors acknowledged a large placebo 
effect with regards to GI symptom scores and overall treatment 
effect, which has been previously demonstrated in numerous 
other studies of GI symptoms. Subjective clinical improvement 
may reﬂ  ect patient reassurance that more serious diseases 
have been excluded by close serial observation in a clinical 
trial environment. The authors concluded that esomeprazole 
improves upper gastrointestinal symptoms associated with 
chronic NSAID use, including selective COX-2 inhibitors.50
Conclusion
High healing rates of peptic ulcers related to chronic NSAID use 
are achieved with medical therapy, particularly if the causative 
agent can be discontinued. The American Gastroenterological 
Association (AGA) recently released a consensus statement 
regarding the use of NSAIDs following a panel discussion 
of physicians in gastroenterology, rheumatology, cardiology, 
and internal medicine. The panel emphasized a careful review 
of treatment indications and risk factors, taking into careful 
consideration risks for both gastrointestinal and cardiovas-
cular complications.51 Recommendations are summarized 
in Figure 1. If the causative agent cannot be discontinued, a 
A. Primary treatment of endoscopically confirmed peptic ulcer disease 
1. Perform careful risk assessment including gastrointestinal and  
cardiovascular risks 
2. Discontinue NSAID/aspirin, if possible 
3. Eradicate Helicobacter pylori infection, if present 
4. Antisecretory therapy to promote ulcer healing (PPIs are superior to 
H2RAs)
B. Prevention of NSAID-associated ulcer recurrence (ie, primary or secondary 
prophylaxis)
1. Perform careful risk assessment including gastrointestinal and  
cardiovascular risks 
2. Eradicate Helicobacter pylori infection, if present 
3. Consider substitution for a non-NSAID analgesic 
4. Consider dose reduction of NSAID 
5. Add PPI co-therapy if NSAID is continued (misoprostol may be
considered as second line agent, if tolerated)   
6. Consider switching to COX-2 inhibitor after careful assessment of
cardiovascular risk factors
Figure 1 Management strategies for NSAID-associated gastrointestinal complications.Therapeutics and Clinical Risk Management 2009:5 72
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reduced dose or switch to a more COX-2 selective NSAID in 
conjunction with co-administration of PPIs to promote ulcer 
healing should be considered. Misoprostol has been shown to 
be effective in reducing the risk of gastric ulcers in patients at 
high risk for complications from NSAIDs including the elderly 
and patients with previous history of peptic ulcer disease. It 
has not been demonstrated to reduce the risk of duodenal ulcer-
ations nor reduction in symptoms related to chronic NSAIDs. 
Moreover, misoprostol has a high frequency of intolerance due 
to gastrointestinal side effects. H2-receptor antagonist therapy 
is inadequate for patients receiving NSAIDs with risk factors 
for GI complications; moreover, they have been supplanted 
by the highly efﬁ  cacious and well tolerated proton pump 
inhibitors. Lansoprazole has been shown to be effective in 
the primary treatment and secondary prophylaxis of NSAID-
associated peptic ulcer disease, including maintenance therapy 
following resolution of duodenal ulcers. Esomeprazole is 
the only proton pump inhibitor shown to be effective in both 
primary and secondary prophylaxis of NSAID-associated 
peptic ulcer disease. Esomeprazole has also been shown to 
be highly effective in reducing non-ulcer related symptoms 
associated with chronic NSAID use and may help reduce risk 
of bleeding from non-NSAID antiplatelet drugs. The afore-
mentioned clinical studies provide supportive evidence for the 
use of antisecretory medicine, especially PPIs, in the primary 
treatment of NSAID-associated peptic ulcer disease. Peptic 
ulcer disease and related complications may be prevented 
in chronic NSAID users with primary prophylactic use of 
adequate doses of misoprostol and anti-secretory medicines, 
especially PPIs. Aggressive prevention strategies should be 
undertaken in high-risk patients especially those with a history 
of peptic ulcer disease to prevent against recurrent peptic ulcer 
disease and its associated complications.
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